# Validation Package Deliverables Checklist

**Version**: 1.0
**Last Updated**: 2025-10-24
**Purpose**: Comprehensive checklist for requesting and evaluating vendor validation documentation

> **Use This**: When evaluating vendor validation package before system selection
> **See**: spec/prd-validation.md for detailed validation requirements
> **See**: validation/vendor-scorecard.md for scoring evaluation

---

## Instructions

**For Each Item**:
- â˜ = Not provided or not requested yet
- ğŸ“„ = Received (document available for review)
- âœ… = Received and reviewed (meets requirements)
- âš ï¸ = Received but inadequate (issues identified)
- âŒ = Not available (vendor cannot provide)
- N/A = Not applicable to this system

**Scoring**:
- Critical items marked with â­â­â­ (must have)
- Important items marked with â­â­ (should have)
- Nice-to-have items marked with â­ (bonus)

---

## Section 1: Core Validation Documents

### 1.1 Validation Master Plan (VMP)

**Status**: â˜ **Priority**: â­â­â­ **Critical**: YES

**Requirements**:
- â˜ Document exists and is current (within 12 months)
- â˜ Defines validation strategy and approach
- â˜ Identifies validation team roles and responsibilities
- â˜ Describes risk-based approach to validation
- â˜ Defines acceptance criteria for IQ/OQ/PQ
- â˜ Includes change control procedures
- â˜ Specifies re-validation triggers
- â˜ Contains document control and versioning approach
- â˜ Signed by appropriate authority (QA manager, validation lead)

**Evaluation Questions**:
- Does VMP reference FDA guidance and industry standards (GAMP 5)?
- Is validation approach proportionate to system risk level?
- Are roles clearly defined with named individuals or titles?

**Page Count**: Expected 15-25 pages
**Date Received**: _________
**Reviewed By**: _________
**Notes**:
```


```

---

### 1.2 User Requirements Specification (URS)

**Status**: â˜ **Priority**: â­â­â­ **Critical**: YES

**Requirements**:
- â˜ Document exists and is comprehensive
- â˜ Each requirement has unique identifier (e.g., URS-001)
- â˜ Functional requirements clearly defined
- â˜ Non-functional requirements included (performance, security, usability)
- â˜ Data requirements specified
- â˜ Compliance requirements listed (FDA 21 CFR Part 11, ALCOA+)
- â˜ User role requirements defined
- â˜ Audit trail requirements specified
- â˜ Report and export requirements included
- â˜ Requirements categorized by priority (critical, important, nice-to-have)
- â˜ Requirements are testable (verifiable)

**Evaluation Questions**:
- Do requirements align with our clinical trial needs?
- Are all compliance requirements (21 CFR Part 11) addressed?
- Can each requirement be traced to a test case?

**Expected Coverage**:
- â˜ Authentication and authorization
- â˜ Data entry and validation
- â˜ Audit trail and compliance
- â˜ Offline functionality
- â˜ Multi-device synchronization
- â˜ Reporting and export
- â˜ Security controls
- â˜ Multi-sponsor isolation

**Page Count**: Expected 30-50 pages
**Total Requirements**: ______ (typical: 80-150 requirements)
**Date Received**: _________
**Notes**:
```


```

---

### 1.3 Functional Specifications (FS)

**Status**: â˜ **Priority**: â­â­â­ **Critical**: YES

**Requirements**:
- â˜ Technical description of how system implements URS
- â˜ System architecture diagrams included
- â˜ Database schema documented
- â˜ Security architecture described (RBAC, RLS)
- â˜ Authentication/authorization mechanisms detailed
- â˜ Data flow diagrams provided
- â˜ Interface specifications (APIs, mobile app, web portal)
- â˜ Error handling and recovery procedures
- â˜ Each specification references URS requirement(s)
- â˜ Traceability matrix: FS â†” URS

**Evaluation Questions**:
- Does architecture support our requirements (offline, multi-sponsor)?
- Is Event Sourcing properly implemented for audit trail?
- Are security controls database-enforced (RLS)?

**Technical Areas Covered**:
- â˜ Mobile application architecture
- â˜ Web portal architecture
- â˜ Backend/API architecture
- â˜ Database design (Event Sourcing)
- â˜ Authentication system (Supabase Auth)
- â˜ Multi-sponsor isolation design
- â˜ Offline synchronization mechanism
- â˜ Encryption (in transit and at rest)

**Page Count**: Expected 60-100 pages
**Date Received**: _________
**Notes**:
```


```

---

### 1.4 Risk Assessment

**Status**: â˜ **Priority**: â­â­â­ **Critical**: YES

**Requirements**:
- â˜ Risk assessment document exists
- â˜ Methodology described (e.g., FMEA, risk matrix)
- â˜ All potential failure modes identified
- â˜ Impact assessment (patient safety, data integrity, compliance)
- â˜ Probability/likelihood assessed
- â˜ Risk priority numbers (RPN) or risk levels calculated
- â˜ Mitigation strategies defined for high/medium risks
- â˜ Residual risk documented after mitigation
- â˜ Risk assessment informed validation test coverage

**Risk Categories**:
- â˜ Data integrity risks
- â˜ Security risks (unauthorized access, breach)
- â˜ Compliance risks (audit trail, FDA requirements)
- â˜ System availability risks (downtime, offline sync failures)
- â˜ User error risks
- â˜ Multi-sponsor isolation risks

**High-Risk Areas** (must have extensive testing):
- â˜ Audit trail integrity
- â˜ Multi-sponsor data isolation
- â˜ Offline data synchronization
- â˜ Row-level security policies
- â˜ Authentication and authorization

**Date Received**: _________
**Notes**:
```


```

---

### 1.5 Installation Qualification (IQ)

**Status**: â˜ **Priority**: â­â­â­ **Critical**: YES

**IQ Protocol Requirements**:
- â˜ IQ Protocol document exists
- â˜ Defines what will be verified during installation
- â˜ Test cases for hardware/infrastructure
- â˜ Test cases for software version verification
- â˜ Test cases for database configuration
- â˜ Test cases for security settings
- â˜ Test cases for backup systems
- â˜ Expected results clearly defined
- â˜ Evidence requirements specified

**IQ Report Requirements**:
- â˜ IQ Report document exists (from previous installation)
- â˜ All protocol test cases executed
- â˜ Pass/fail results documented
- â˜ Evidence attached (screenshots, configuration exports)
- â˜ Deviations documented and resolved
- â˜ Signed by tester and reviewer

**Key IQ Areas**:
- â˜ Server/hosting environment verification
- â˜ PostgreSQL installation and configuration
- â˜ Supabase setup verification
- â˜ SSL/TLS certificate verification
- â˜ Database extensions (pgaudit, etc.)
- â˜ RLS enabled on all tables
- â˜ Backup system configuration
- â˜ Monitoring system setup

**Date Received**: _________
**Installation Tested**: â˜ Development â˜ Validation â˜ Production (previous customer)
**Notes**:
```


```

---

### 1.6 Operational Qualification (OQ)

**Status**: â˜ **Priority**: â­â­â­ **Critical**: YES

**OQ Protocol Requirements**:
- â˜ OQ Protocol document exists
- â˜ Test cases cover all URS requirements
- â˜ Each test has unique ID
- â˜ Expected vs. actual result format defined
- â˜ Evidence requirements specified
- â˜ Traceability to URS requirements

**OQ Report Requirements**:
- â˜ OQ Report exists (from previous validation)
- â˜ All test cases executed
- â˜ Pass/fail results for each test
- â˜ Evidence provided (screenshots, logs, data exports)
- â˜ Deviations documented and resolved
- â˜ Signed by tester and independent QA reviewer

**Critical Test Areas** (must be covered):

**Authentication & Authorization**:
- â˜ Valid login test
- â˜ Invalid password test
- â˜ Two-factor authentication test
- â˜ Session timeout test
- â˜ Password complexity enforcement

**RBAC Testing**:
- â˜ Patient data isolation (patient sees only own data)
- â˜ Investigator site-scoped access
- â˜ Sponsor global access (de-identified)
- â˜ Auditor read-only access
- â˜ Role-based feature access

**RLS Policy Testing**:
- â˜ Row-level security prevents cross-patient access
- â˜ Site scoping enforced at database level
- â˜ RLS cannot be bypassed by application code
- â˜ Multi-sponsor isolation verified

**Audit Trail Testing**:
- â˜ CREATE events captured
- â˜ UPDATE events captured with reason
- â˜ DELETE events captured
- â˜ All events include user_id, timestamp, action, payload
- â˜ Audit events immutable (cannot UPDATE or DELETE)
- â˜ Event Sourcing integrity verified

**Data Entry & Sync**:
- â˜ Online data entry
- â˜ Offline data capture
- â˜ Sync after offline
- â˜ Multi-device conflict resolution
- â˜ Data validation rules

**Security Testing**:
- â˜ SQL injection prevention
- â˜ XSS prevention
- â˜ CSRF protection
- â˜ Encryption in transit (SSL/TLS)
- â˜ Encryption at rest

**Export & Reporting**:
- â˜ Data export functionality
- â˜ Audit trail export
- â˜ Report generation

**Page Count**: Expected 80-150 pages
**Total Test Cases**: ______ (typical: 100-200 tests)
**Pass Rate**: ______ % (expect: >95%)
**Date Received**: _________
**Notes**:
```


```

---

### 1.7 Performance Qualification (PQ)

**Status**: â˜ **Priority**: â­â­â­ **Critical**: YES

**PQ Protocol Requirements**:
- â˜ PQ Protocol exists
- â˜ End-to-end workflow scenarios defined
- â˜ Performance benchmarks specified
- â˜ Load testing parameters defined
- â˜ User acceptance criteria

**PQ Report Requirements**:
- â˜ PQ Report exists (from previous validation)
- â˜ All scenarios executed
- â˜ Performance metrics captured
- â˜ User feedback documented (if applicable)
- â˜ Pass/fail against acceptance criteria
- â˜ Evidence provided

**Critical PQ Scenarios**:

**Patient Workflow**:
- â˜ Enrollment end-to-end
- â˜ 7-day diary entry sequence
- â˜ Offline entry and sync
- â˜ Historical data review
- â˜ Data export

**Investigator Workflow**:
- â˜ Site selection and patient review
- â˜ Data query generation
- â˜ Annotation creation
- â˜ Report generation

**Sponsor Workflow**:
- â˜ User account management
- â˜ Multi-site data review
- â˜ Aggregate reporting
- â˜ Audit trail review

**Performance Testing**:
- â˜ Concurrent user load test (50-100+ users)
- â˜ Large dataset handling (500-1000+ patients)
- â˜ Report generation performance
- â˜ Sync performance with backlog
- â˜ Database query performance

**Data Integrity**:
- â˜ Complete audit trail verification
- â˜ Event Sourcing reconstruction accuracy
- â˜ Tamper detection testing
- â˜ Backup and restore verification

**Security**:
- â˜ Penetration testing results
- â˜ Privilege escalation attempts
- â˜ Multi-sponsor boundary testing

**Performance Benchmarks**:
- â˜ Average response time < 2 seconds
- â˜ 95th percentile < 5 seconds
- â˜ Error rate < 0.1%
- â˜ Sync completes within 30 seconds

**Date Received**: _________
**Notes**:
```


```

---

### 1.8 Traceability Matrix

**Status**: â˜ **Priority**: â­â­â­ **Critical**: YES

**Requirements**:
- â˜ Traceability Matrix document exists
- â˜ Links URS â†’ FS â†’ OQ/PQ tests
- â˜ 100% URS requirement coverage
- â˜ All tests show pass status
- â˜ Bi-directional traceability (forward and backward)

**Matrix Structure**:
```
URS-ID | Description | FS-ID | OQ Test | PQ Test | Status
-------|-------------|-------|---------|---------|-------
```

**Coverage Verification**:
- â˜ All URS requirements have corresponding FS
- â˜ All URS requirements have at least one test
- â˜ All tests passed
- â˜ No orphan tests (tests not linked to requirements)

**Format**: â˜ Excel â˜ PDF â˜ Database â˜ Other: _________
**Date Received**: _________
**Notes**:
```


```

---

### 1.9 Validation Summary Report

**Status**: â˜ **Priority**: â­â­â­ **Critical**: YES

**Requirements**:
- â˜ Summary report exists
- â˜ Executive summary included
- â˜ Validation scope and objectives stated
- â˜ Methodology described
- â˜ IQ/OQ/PQ results summarized
- â˜ Deviations summary (count, severity, resolution)
- â˜ Traceability matrix summary (coverage %)
- â˜ Risk assessment summary
- â˜ Overall conclusion and recommendation
- â˜ Signed by validation lead, QA, and sponsor/customer

**Key Metrics**:
- Total requirements: ______
- Total test cases: ______
- Tests passed: ______ (____%)
- Tests failed (resolved): ______
- Deviations: ______ (all resolved: â˜ Yes â˜ No)
- Coverage: ______%

**Final Recommendation**:
- â˜ System approved for production use
- â˜ System suitable for FDA-regulated clinical trials

**Signatures Present**:
- â˜ Validation Team Lead
- â˜ Quality Assurance Manager
- â˜ IT/System Owner
- â˜ Customer/Sponsor Representative

**Date Received**: _________
**Notes**:
```


```

---

## Section 2: Standard Operating Procedures (SOPs)

**Priority**: â­â­ **Critical**: NO (but highly recommended)

### 2.1 System Access Management SOP

**Status**: â˜

- â˜ User account creation/deletion procedures
- â˜ Password reset procedures
- â˜ Role assignment procedures
- â˜ Access review procedures
- â˜ Multi-factor authentication setup

**Date Received**: _________

---

### 2.2 Data Entry and Correction SOP

**Status**: â˜

- â˜ Data entry procedures
- â˜ Error correction procedures
- â˜ Audit trail justification requirements
- â˜ Annotation procedures

**Date Received**: _________

---

### 2.3 Backup and Recovery SOP

**Status**: â˜

- â˜ Backup frequency and procedures
- â˜ Backup verification procedures
- â˜ Recovery procedures
- â˜ Recovery testing schedule

**Date Received**: _________

---

### 2.4 Change Control SOP

**Status**: â˜ **Priority**: â­â­â­ (Upgrade to critical)

- â˜ Change request process
- â˜ Impact assessment procedures
- â˜ Testing requirements before deployment
- â˜ Re-validation triggers clearly defined
- â˜ Change approval authority
- â˜ Version control procedures

**Date Received**: _________

---

### 2.5 Incident Response SOP

**Status**: â˜

- â˜ Issue reporting procedures
- â˜ Severity classification
- â˜ Escalation procedures
- â˜ Root cause analysis
- â˜ CAPA (Corrective and Preventive Actions)

**Date Received**: _________

---

### 2.6 System Monitoring SOP

**Status**: â˜

- â˜ Daily health check procedures
- â˜ Performance monitoring
- â˜ Security monitoring
- â˜ Alert response procedures

**Date Received**: _________

---

### 2.7 Audit and Compliance SOP

**Status**: â˜ **Priority**: â­â­â­ (Upgrade to critical)

- â˜ Audit log review procedures
- â˜ Compliance monitoring
- â˜ Regulatory inspection preparation
- â˜ Audit log export for FDA submission

**Date Received**: _________

---

## Section 3: Training Materials

**Priority**: â­â­

### 3.1 Patient User Guide

**Status**: â˜

- â˜ Mobile app user guide exists
- â˜ Enrollment instructions
- â˜ Troubleshooting guide
- â˜ Privacy notice
- â˜ Written at appropriate literacy level

**Date Received**: _________

---

### 3.2 Investigator Portal Guide

**Status**: â˜

- â˜ Web portal user guide
- â˜ Data review procedures
- â˜ Query management
- â˜ Compliance requirements training

**Date Received**: _________

---

### 3.3 Sponsor Administrator Guide

**Status**: â˜

- â˜ Administrator guide
- â˜ User management procedures
- â˜ Report generation instructions
- â˜ Audit trail access procedures

**Date Received**: _________

---

### 3.4 System Administrator Guide

**Status**: â˜ **Priority**: â­â­â­

- â˜ System configuration guide
- â˜ Monitoring procedures
- â˜ Backup/recovery procedures
- â˜ Incident response procedures
- â˜ Troubleshooting guide

**Date Received**: _________

---

### 3.5 Training Records

**Status**: â˜

- â˜ Training completion logs template
- â˜ Assessment/test (if applicable)
- â˜ Curriculum versioning approach
- â˜ Re-training schedule defined

**Date Received**: _________

---

## Section 4: Supporting Technical Documentation

**Priority**: â­â­

### 4.1 System Architecture Documentation

**Status**: â˜

- â˜ System architecture diagrams
- â˜ Network architecture
- â˜ Multi-sponsor deployment architecture
- â˜ Data flow diagrams
- â˜ Technology stack documentation

**Date Received**: _________

---

### 4.2 Database Documentation

**Status**: â˜ **Priority**: â­â­â­

- â˜ Database schema (ERD)
- â˜ Event Sourcing design documentation
- â˜ Table definitions
- â˜ Index documentation
- â˜ RLS policy documentation (SQL code)
- â˜ Trigger and function documentation

**Date Received**: _________

---

### 4.3 API Documentation

**Status**: â˜

- â˜ API endpoint specifications
- â˜ Authentication/authorization for APIs
- â˜ Request/response formats
- â˜ Error codes and handling
- â˜ Rate limiting

**Date Received**: _________

---

### 4.4 Security Testing Results

**Status**: â˜ **Priority**: â­â­â­

- â˜ Penetration testing report
- â˜ Vulnerability assessment
- â˜ Findings and remediation
- â˜ Testing date and firm
- â˜ Current (within 12 months)

**Date Received**: _________
**Testing Date**: _________
**Testing Firm**: _________

---

### 4.5 Performance Testing Results

**Status**: â˜

- â˜ Load testing report
- â˜ Concurrent user benchmarks
- â˜ Response time metrics
- â˜ Scalability analysis

**Date Received**: _________

---

## Section 5: Quality System Documentation

**Priority**: â­â­

### 5.1 Quality Management System

**Status**: â˜

- â˜ ISO 13485 certification (medical device QMS)
- â˜ Quality manual
- â˜ Document control procedures
- â˜ Internal audit procedures

**ISO 13485 Certified**: â˜ Yes â˜ No â˜ In Progress
**Certificate Expiration**: _________

---

### 5.2 Software Development Lifecycle

**Status**: â˜

- â˜ SDLC documentation
- â˜ Coding standards
- â˜ Code review procedures
- â˜ Version control procedures
- â˜ Testing procedures (unit, integration)

**Date Received**: _________

---

### 5.3 Bug Tracking and Resolution

**Status**: â˜

- â˜ Bug tracking system access (or reports)
- â˜ Bug prioritization criteria
- â˜ Bug resolution SLA
- â˜ Known issues log

**Date Received**: _________

---

## Section 6: Regulatory and Compliance

**Priority**: â­â­â­

### 6.1 FDA Submission History

**Status**: â˜

- â˜ List of FDA submissions using this system
- â˜ Submission dates and drug/trial names (if shareable)
- â˜ Outcomes (approved, pending, rejected)
- â˜ Any FDA observations or questions

**Successful FDA Submissions**: ______ (count)
**Date Received**: _________

---

### 6.2 Regulatory Inspection History

**Status**: â˜

- â˜ FDA inspection history (if any)
- â˜ Inspection findings (Form 483)
- â˜ CAPA for findings
- â˜ Closure status

**Inspections**: â˜ None â˜ Yes (details: _____________)
**Date Received**: _________

---

### 6.3 Compliance Certifications

**Status**: â˜

- â˜ 21 CFR Part 11 compliance statement
- â˜ HIPAA compliance (if applicable)
- â˜ GDPR compliance (if applicable)
- â˜ SOC 2 report (security and availability)

**SOC 2 Type**: â˜ Type I â˜ Type II â˜ None
**Report Date**: _________

---

### 6.4 Warning Letters or Violations

**Status**: â˜

- â˜ Any FDA warning letters related to this system
- â˜ Any regulatory violations
- â˜ Resolution status

**Issues**: â˜ None â˜ Yes (explain: _____________)

---

## Section 7: Customer References

**Priority**: â­â­â­

### 7.1 Reference Customers

**Status**: â˜

- â˜ List of existing pharmaceutical sponsors using system
- â˜ Contact information for references
- â˜ Trial phases using system (Phase 1, 2, 3, 4)
- â˜ Therapeutic areas

**Reference Customers** (count): ______
**Phase 1 Trials**: ______ (how many)
**Date Received**: _________

---

### 7.2 Case Studies or Testimonials

**Status**: â˜

- â˜ Published case studies
- â˜ Customer testimonials
- â˜ Success metrics (enrollment rates, data quality, etc.)

**Date Received**: _________

---

### 7.3 Reference Calls

**Status**: â˜

**Reference 1**:
- Company: _____________
- Contact: _____________
- Call Date: _____________
- Notes:
```


```

**Reference 2**:
- Company: _____________
- Contact: _____________
- Call Date: _____________
- Notes:
```


```

---

## Section 8: Vendor Information

**Priority**: â­â­

### 8.1 Company Background

**Status**: â˜

- â˜ Company profile
- â˜ Years in business
- â˜ Clinical trial system experience
- â˜ Team size and qualifications
- â˜ Financial stability

**Years in Business**: ______
**Employees**: ______

---

### 8.2 Support and Services

**Status**: â˜

- â˜ Support SLA documentation
- â˜ Support hours (24/7, business hours, etc.)
- â˜ Response time commitments
- â˜ Escalation procedures
- â˜ Validation consulting services availability

**Support Hours**: _____________
**Response SLA**: _____________

---

### 8.3 Roadmap and Updates

**Status**: â˜

- â˜ Product roadmap (future features)
- â˜ Update/release schedule
- â˜ How updates are validated
- â˜ Customer input on roadmap

**Date Received**: _________

---

## Section 9: Contractual and Pricing

**Priority**: â­â­

### 9.1 Licensing and Contracts

**Status**: â˜

- â˜ License agreement (draft or template)
- â˜ Data ownership terms
- â˜ Data portability provisions
- â˜ Termination clauses
- â˜ Liability and indemnification

**Date Received**: _________

---

### 9.2 Pricing

**Status**: â˜

- â˜ Pricing model (per user, per patient, per study, etc.)
- â˜ Setup/implementation fees
- â˜ Annual maintenance/support fees
- â˜ Validation consulting fees
- â˜ Training fees

**Date Received**: _________

---

### 9.3 Service Level Agreements (SLA)

**Status**: â˜ **Priority**: â­â­â­

- â˜ Uptime guarantees (expect: 99.9% or higher)
- â˜ Incident response times
- â˜ Planned maintenance windows
- â˜ Penalties for SLA violations
- â˜ Data backup guarantees

**Uptime Guarantee**: ______%
**Date Received**: _________

---

## Completion Summary

**Total Items**: 95+

**Status Count**:
- â˜ Not requested: ______
- ğŸ“„ Received: ______
- âœ… Reviewed and approved: ______
- âš ï¸ Received but inadequate: ______
- âŒ Not available: ______
- N/A: ______

**Critical Items (â­â­â­)**:
- Total critical: ______ (approximate: 25)
- Critical received: ______
- Critical approved: ______

**Critical Item Completion**: ______% (need >90% to proceed)

---

## Decision Criteria

### GREEN LIGHT (Proceed to Contract Negotiation)

**Criteria**:
- âœ… All critical validation documents received and approved
- âœ… Traceability matrix shows 100% coverage
- âœ… Risk assessment comprehensive
- âœ… Change control and audit SOPs in place
- âœ… At least 2 successful reference customers
- âœ… No unresolved FDA warning letters
- âœ… Validation package <12 months old

**Decision**: PROCEED

---

### YELLOW LIGHT (Proceed with Caution / Conditions)

**Criteria**:
- âš ï¸ Most critical documents received, minor gaps
- âš ï¸ Validation package >12 months old (re-validation needed)
- âš ï¸ Limited reference customers (1-2)
- âš ï¸ Some inadequate documentation (can be improved)

**Conditions**:
- Vendor commits to providing missing items within 30 days
- Pilot validation before full production
- Sponsor performs additional independent validation

**Decision**: CONDITIONAL PROCEED

---

### RED LIGHT (Do Not Proceed)

**Criteria**:
- âŒ Core validation documents missing (IQ/OQ/PQ)
- âŒ No traceability matrix or <80% coverage
- âŒ No FDA submission history
- âŒ Active FDA warning letter or compliance issues
- âŒ No reference customers
- âŒ Vendor cannot provide critical documents

**Decision**: DO NOT PROCEED

---

## Next Steps

**After Checklist Completion**:

1. **Score Package**: Use vendor-scorecard.md to quantify evaluation
2. **Schedule Reference Calls**: Speak with 2-3 existing customers
3. **Gap Analysis**: Document missing or inadequate items
4. **Vendor Discussion**: Present gaps and request remediation plan
5. **Decision Meeting**: Sponsor team reviews and makes GO/NO-GO decision

**Completed By**: _____________
**Date**: _____________
**Recommendation**: â˜ Proceed â˜ Conditional â˜ Do Not Proceed

---

## Appendix: Document Request Template

**Use this email template to request validation package from vendor**:

---

**Subject**: Validation Documentation Request for [System Name]

Dear [Vendor Contact],

We are evaluating [System Name] for use in our FDA-regulated Phase 1 clinical trial. As part of our due diligence, we require comprehensive validation documentation to assess system suitability.

Please provide the following documents:

**Critical Validation Documents**:
1. Validation Master Plan (VMP)
2. User Requirements Specification (URS)
3. Functional Specifications (FS)
4. Risk Assessment
5. Installation Qualification (IQ) Protocol and Report
6. Operational Qualification (OQ) Protocol and Report
7. Performance Qualification (PQ) Protocol and Report
8. Traceability Matrix (URS to FS to Tests)
9. Validation Summary Report (signed)

**Supporting Documentation**:
10. Standard Operating Procedures (Change Control, Audit, Backup/Recovery)
11. System architecture and database documentation
12. Security and penetration testing reports (within 12 months)
13. Training materials for all user roles
14. FDA submission history (if applicable)
15. Reference customer contacts

**Compliance Information**:
16. 21 CFR Part 11 compliance statement
17. SOC 2 report (if available)
18. ISO 13485 certificate (if applicable)

Please also include information on:
- Support SLAs and response times
- Pricing and licensing terms
- Validation consulting services availability

**Timeline**: We request these documents within [2 weeks / 30 days].

Thank you for your assistance. Please contact me if you have questions.

Best regards,
[Your Name]
[Your Title]
[Contact Information]

---

## References

- **Validation Requirements**: spec/prd-validation.md
- **Execution Procedures**: validation/ops-validation.md
- **Scoring Evaluation**: validation/vendor-scorecard.md
